Drugs / TetraVax-DV Vaccine-Admixture 4
last change Jun 2012 re-read 3 minutes ago

TetraVax-DV Vaccine-Admixture 4

Vaccine

Developed for
dengue disease
Investigated by
Johns Hopkins Bloomberg School of Public Health · National Institute of Allergy and Infectious Diseases (NIAID)

Trials 1

20112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT01072786 Jul 2010 → Jun 2012 dengue disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as TetraVax-DV Vaccine-Admixture 4 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01072786 ↗
Modality Vaccine “a recombinant live attenuated tetravalent dengue virus vaccine” NCT01072786 ↗
Route Subcutaneous “One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 4” NCT01072786 ↗